These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7796417

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.
    Sun Y, Hildesheim A, Lanier AE, Cao Y, Yao KT, Raab-Traub N, Yang CS.
    Oncogene; 1995 Feb 16; 10(4):785-8. PubMed ID: 7862458
    [Abstract] [Full Text] [Related]

  • 23. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck.
    Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL.
    Cancer Res; 1994 Oct 01; 54(19):5050-3. PubMed ID: 7923115
    [Abstract] [Full Text] [Related]

  • 24. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK.
    Cancer Res; 1997 Nov 01; 57(21):4868-75. PubMed ID: 9354451
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
    Ryan A, Al-Jehani RM, Mulligan KT, Jacobs IJ.
    Gynecol Oncol; 1998 Jan 01; 68(1):14-7. PubMed ID: 9454653
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE, Gorgoulis V, Mariatos G, Zacharatos P, Kotsinas A, Garinis G, Trigidou R, Karameris A, Tsimara-Papastamatiou H, Kouloukousa M, Manolis EN, Kittas C.
    Anticancer Res; 1999 Jan 01; 19(3A):1893-9. PubMed ID: 10470133
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
    Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN.
    Cancer Res; 1997 Jul 01; 57(13):2703-9. PubMed ID: 9205080
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.
    Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1993-8. PubMed ID: 9816158
    [Abstract] [Full Text] [Related]

  • 36. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.
    Liu Q, Yan YX, McClure M, Nakagawa H, Fujimura F, Rustgi AK.
    Oncogene; 1995 Feb 02; 10(3):619-22. PubMed ID: 7845688
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.
    Merbs SL, Sidransky D.
    Invest Ophthalmol Vis Sci; 1999 Mar 02; 40(3):779-83. PubMed ID: 10067984
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.